Clinical Trial Update: Sickle Cell Disease and CardiovAscular Risk - Red Cell Exchange Trial (SCD-CARRE) [Phase 3]

View source ↗

Summary

Phase 3 trial updating sickle cell disease with a focus on cardiovascular risk through red cell exchange therapy (SCD-CARRE).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Snippet

Sponsor: University of Pittsburgh | Conditions: Sickle Cell Disease | Phase 3 | Status: ACTIVE_NOT_RECRUITING